{"id":"NCT00483548","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Adjunctive Ziprasidone in the Treatment of Bipolar I Depression","officialTitle":"A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2007-06-07","resultsPosted":"2010-02-23","lastUpdate":"2021-03-10"},"enrollment":298,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder","Depression, Bipolar"],"interventions":[{"type":"DRUG","name":"Ziprasidone","otherNames":["Geodon, Zeldox"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ziprasidone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if a treatment regimen of ziprasidone plus a mood stabilizer is safe and effective in the short term treatment of Bipolar I Depression. Ziprasidone will be added to lithium, valproate or lamotrigine after the patient has been on a therapeutic dose of one of these mood stabilizers for at least 4 weeks.","primaryOutcome":{"measure":"Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline, Week 6","effectByArm":[{"arm":"Ziprasidone","deltaMin":-14.7,"sd":10.7},{"arm":"Placebo","deltaMin":-13.2,"sd":10.4}],"pValues":[{"comp":"OG000 vs OG001","p":"0.7921"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":70,"countries":["United States","Australia","India"]},"refs":{"pmids":["21672493"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281158&StudyName=Adjunctive%20Ziprasidone%20in%20the%20Treatment%20of%20Bipolar%20I%20Depression"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":147},"commonTop":["Somnolence","Headache","Dizziness","Sedation","Insomnia"]}}